Response of Novel Biomarkers to BNP Infusion in Patients with Decompensated Heart Failure: A Multimarker Paradigm View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-08-14

AUTHORS

Wayne L. Miller, Karen A. Hartman, David O. Hodge, Stacy Hartman, Joachim Struck, Nils G. Morgenthaler, Andreas Bergmann, Allan S. Jaffe

ABSTRACT

Multibiomarker paradigms have been proposed to diagnose, define progression, and to monitor therapy of heart failure (HF) patients. The aim of this study was to evaluate the prognostic and therapy-monitoring potential of four novel biomarkers (copeptin, midregional proatrial natriuretic peptide (MR-proANP), neopterin, and procalcitonin) which have been shown to be elevated in the plasma of patients with HF and reported to have prognostic value. In a prospective study of 40 patients hospitalized for decompensated HF and who received nesiritide infusions as part of their care, blood was drawn before, during, and postinfusion and assayed for the novel biomarkers. B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) which were previously measured and reported in this cohort were also included in the analyses. All biomarkers were elevated at baseline prior to nesiritide infusion, but copeptin, MR-proANP, and NT-proBNP demonstrated significant acute reductions in plasma levels in response to therapy. Copeptin levels were higher in posthospital nonsurvivors and by proportional hazards model were associated with an increased mortality risk (p = 0.04). Procalcitonin and neopterin added no incremental information on response to therapy or risk stratification. In contrast, copeptin and MR-proANP appear to have potential for monitoring acute responses to therapy. Only copeptin and BNP contributed to risk stratification in this cohort of advanced HF patients, but the conjoint use of BNP or NT-proBNP does not appear to impact the prognostic value of copeptin alone. These results are hypothesis generating to stimulate additional investigation. More... »

PAGES

526-535

References to SciGraph publications

  • 1998-04. Structure–Function Relationships of the Vasopressin Prohormone Domains in CELLULAR AND MOLECULAR NEUROBIOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s12265-009-9121-x

    DOI

    http://dx.doi.org/10.1007/s12265-009-9121-x

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1003860827

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/20560012


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Atrial Natriuretic Factor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Biomarkers", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Calcitonin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Calcitonin Gene-Related Peptide", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cardiovascular Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Monitoring", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Glycopeptides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Heart Failure", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Infusions, Intravenous", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kaplan-Meier Estimate", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Minnesota", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Natriuretic Peptide, Brain", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neopterin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Predictive Value of Tests", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Precursors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Risk Assessment", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Risk Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Time Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Mayo Clinic, 200 First Street, SW, 55905, Rochester, MN, USA", 
              "id": "http://www.grid.ac/institutes/grid.66875.3a", 
              "name": [
                "Mayo Clinic, 200 First Street, SW, 55905, Rochester, MN, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Miller", 
            "givenName": "Wayne L.", 
            "id": "sg:person.01166460626.19", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166460626.19"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Mayo Clinic, 200 First Street, SW, 55905, Rochester, MN, USA", 
              "id": "http://www.grid.ac/institutes/grid.66875.3a", 
              "name": [
                "Mayo Clinic, 200 First Street, SW, 55905, Rochester, MN, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hartman", 
            "givenName": "Karen A.", 
            "id": "sg:person.01234574026.84", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234574026.84"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Mayo Clinic, 200 First Street, SW, 55905, Rochester, MN, USA", 
              "id": "http://www.grid.ac/institutes/grid.66875.3a", 
              "name": [
                "Mayo Clinic, 200 First Street, SW, 55905, Rochester, MN, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hodge", 
            "givenName": "David O.", 
            "id": "sg:person.01321577767.50", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01321577767.50"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Mayo Clinic, 200 First Street, SW, 55905, Rochester, MN, USA", 
              "id": "http://www.grid.ac/institutes/grid.66875.3a", 
              "name": [
                "Mayo Clinic, 200 First Street, SW, 55905, Rochester, MN, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hartman", 
            "givenName": "Stacy", 
            "id": "sg:person.0646201724.19", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646201724.19"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "B.R.A.H.M.S. Aktiengesellschaft, Hennigsdorf, Berlin, Germany", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "B.R.A.H.M.S. Aktiengesellschaft, Hennigsdorf, Berlin, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Struck", 
            "givenName": "Joachim", 
            "id": "sg:person.01136323224.23", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136323224.23"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "B.R.A.H.M.S. Aktiengesellschaft, Hennigsdorf, Berlin, Germany", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "B.R.A.H.M.S. Aktiengesellschaft, Hennigsdorf, Berlin, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Morgenthaler", 
            "givenName": "Nils G.", 
            "id": "sg:person.0707647370.62", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707647370.62"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "B.R.A.H.M.S. Aktiengesellschaft, Hennigsdorf, Berlin, Germany", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "B.R.A.H.M.S. Aktiengesellschaft, Hennigsdorf, Berlin, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bergmann", 
            "givenName": "Andreas", 
            "id": "sg:person.01014762623.23", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014762623.23"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Mayo Clinic, 200 First Street, SW, 55905, Rochester, MN, USA", 
              "id": "http://www.grid.ac/institutes/grid.66875.3a", 
              "name": [
                "Mayo Clinic, 200 First Street, SW, 55905, Rochester, MN, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Jaffe", 
            "givenName": "Allan S.", 
            "id": "sg:person.01142743175.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142743175.05"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1023/a:1022564803093", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032855376", 
              "https://doi.org/10.1023/a:1022564803093"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2009-08-14", 
        "datePublishedReg": "2009-08-14", 
        "description": "Multibiomarker paradigms have been proposed to diagnose, define progression, and to monitor therapy of heart failure (HF) patients. The aim of this study was to evaluate the prognostic and therapy-monitoring potential of four novel biomarkers (copeptin, midregional proatrial natriuretic peptide (MR-proANP), neopterin, and procalcitonin) which have been shown to be elevated in the plasma of patients with HF and reported to have prognostic value. In a prospective study of 40 patients hospitalized for decompensated HF and who received nesiritide infusions as part of their care, blood was drawn before, during, and postinfusion and assayed for the novel biomarkers. B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) which were previously measured and reported in this cohort were also included in the analyses. All biomarkers were elevated at baseline prior to nesiritide infusion, but copeptin, MR-proANP, and NT-proBNP demonstrated significant acute reductions in plasma levels in response to therapy. Copeptin levels were higher in posthospital nonsurvivors and by proportional hazards model were associated with an increased mortality risk (p\u2009=\u20090.04). Procalcitonin and neopterin added no incremental information on response to therapy or risk stratification. In contrast, copeptin and MR-proANP appear to have potential for monitoring acute responses to therapy. Only copeptin and BNP contributed to risk stratification in this cohort of advanced HF patients, but the conjoint use of BNP or NT-proBNP does not appear to impact the prognostic value of copeptin alone. These results are hypothesis generating to stimulate additional investigation.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s12265-009-9121-x", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1039754", 
            "issn": [
              "1937-5387", 
              "1937-5395"
            ], 
            "name": "Journal of Cardiovascular Translational Research", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "4", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "2"
          }
        ], 
        "keywords": [
          "novel biomarkers", 
          "nesiritide infusion", 
          "MR-proANP", 
          "NT-proBNP", 
          "prognostic value", 
          "significant acute reduction", 
          "decompensated heart failure", 
          "advanced HF patients", 
          "heart failure patients", 
          "type natriuretic peptide", 
          "plasma of patients", 
          "proportional hazards model", 
          "decompensated HF", 
          "BNP infusion", 
          "HF patients", 
          "failure patients", 
          "copeptin levels", 
          "heart failure", 
          "risk stratification", 
          "prospective study", 
          "natriuretic peptide", 
          "acute reduction", 
          "plasma levels", 
          "mortality risk", 
          "hazards model", 
          "acute response", 
          "patients", 
          "copeptin", 
          "therapy", 
          "BNP", 
          "infusion", 
          "biomarkers", 
          "additional investigation", 
          "cohort", 
          "response", 
          "nonsurvivors", 
          "procalcitonin", 
          "neopterin", 
          "postinfusion", 
          "stratification", 
          "blood", 
          "baseline", 
          "incremental information", 
          "progression", 
          "care", 
          "levels", 
          "risk", 
          "study", 
          "failure", 
          "aim", 
          "peptides", 
          "plasma", 
          "potential", 
          "contrast", 
          "reduction", 
          "terminals", 
          "hypothesis", 
          "HF", 
          "use", 
          "values", 
          "conjoint use", 
          "paradigm", 
          "investigation", 
          "analysis", 
          "results", 
          "part", 
          "information", 
          "model", 
          "Multibiomarker paradigms", 
          "therapy-monitoring potential", 
          "posthospital nonsurvivors", 
          "Multimarker Paradigm"
        ], 
        "name": "Response of Novel Biomarkers to BNP Infusion in Patients with Decompensated Heart Failure: A Multimarker Paradigm", 
        "pagination": "526-535", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1003860827"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s12265-009-9121-x"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "20560012"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s12265-009-9121-x", 
          "https://app.dimensions.ai/details/publication/pub.1003860827"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-01-01T18:20", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_499.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s12265-009-9121-x"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12265-009-9121-x'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12265-009-9121-x'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12265-009-9121-x'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12265-009-9121-x'


     

    This table displays all metadata directly associated to this object as RDF triples.

    282 TRIPLES      22 PREDICATES      122 URIs      113 LITERALS      30 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s12265-009-9121-x schema:about N0185d57a4691468aaf35e470e46ffd6a
    2 N06081110322d453f8f51aa50a373d4ec
    3 N279a3f4175344df0a522d4c2ce1915f9
    4 N6e1a83598ecf4afd8d1cf7882565b511
    5 N7546af984e594cff86c8e5d90302255b
    6 N765c0cc58c684aa2a110011caae52d95
    7 N839860373c2644ff84270bcb8e130900
    8 N854fcaeff14c42119efd64ec91d63d12
    9 N87a2a70101cc40b68f272797b2e80ccc
    10 N8e165edd95bb4e87b1627424a3c4ab8f
    11 N8fe3a4eaf5cf40ae98acaa9dc2b449e1
    12 N94e96bebf9d4484bbe79020035db184d
    13 Na38a85cd84e0400598deec4a27cdabe6
    14 Nadcc9e33cad6444fa22fa16d2029f96c
    15 Nadf10883e15a4688839e9e7d05e77e1e
    16 Nb1caf08914ed489cb20bef8d75ee2965
    17 Nb570b30175684c9e8f75abb0b6acc7d3
    18 Nb5b39bb2166a457ab4d0a0d6f873fd03
    19 Nb6c475ba2c5e4831b7f3436b68acac9e
    20 Nbf0c9b3e4e174f3cb88f84ba635b3a10
    21 Nc0a6a925578248a4a65570bcaa3e0ac4
    22 Ndfc41442814345c1a78b4b20d6a1ee6b
    23 Nffa8a84d0e954918b5ca21cf328814a5
    24 anzsrc-for:11
    25 anzsrc-for:1102
    26 schema:author N550e9a6fda3e42d0b80d6f3df22038e6
    27 schema:citation sg:pub.10.1023/a:1022564803093
    28 schema:datePublished 2009-08-14
    29 schema:datePublishedReg 2009-08-14
    30 schema:description Multibiomarker paradigms have been proposed to diagnose, define progression, and to monitor therapy of heart failure (HF) patients. The aim of this study was to evaluate the prognostic and therapy-monitoring potential of four novel biomarkers (copeptin, midregional proatrial natriuretic peptide (MR-proANP), neopterin, and procalcitonin) which have been shown to be elevated in the plasma of patients with HF and reported to have prognostic value. In a prospective study of 40 patients hospitalized for decompensated HF and who received nesiritide infusions as part of their care, blood was drawn before, during, and postinfusion and assayed for the novel biomarkers. B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) which were previously measured and reported in this cohort were also included in the analyses. All biomarkers were elevated at baseline prior to nesiritide infusion, but copeptin, MR-proANP, and NT-proBNP demonstrated significant acute reductions in plasma levels in response to therapy. Copeptin levels were higher in posthospital nonsurvivors and by proportional hazards model were associated with an increased mortality risk (p = 0.04). Procalcitonin and neopterin added no incremental information on response to therapy or risk stratification. In contrast, copeptin and MR-proANP appear to have potential for monitoring acute responses to therapy. Only copeptin and BNP contributed to risk stratification in this cohort of advanced HF patients, but the conjoint use of BNP or NT-proBNP does not appear to impact the prognostic value of copeptin alone. These results are hypothesis generating to stimulate additional investigation.
    31 schema:genre article
    32 schema:inLanguage en
    33 schema:isAccessibleForFree false
    34 schema:isPartOf N122aa5174ba5473fa5bc1b23ad9f8e24
    35 N9505e16e91884b35a9ab6246af332ac1
    36 sg:journal.1039754
    37 schema:keywords BNP
    38 BNP infusion
    39 HF
    40 HF patients
    41 MR-proANP
    42 Multibiomarker paradigms
    43 Multimarker Paradigm
    44 NT-proBNP
    45 acute reduction
    46 acute response
    47 additional investigation
    48 advanced HF patients
    49 aim
    50 analysis
    51 baseline
    52 biomarkers
    53 blood
    54 care
    55 cohort
    56 conjoint use
    57 contrast
    58 copeptin
    59 copeptin levels
    60 decompensated HF
    61 decompensated heart failure
    62 failure
    63 failure patients
    64 hazards model
    65 heart failure
    66 heart failure patients
    67 hypothesis
    68 incremental information
    69 information
    70 infusion
    71 investigation
    72 levels
    73 model
    74 mortality risk
    75 natriuretic peptide
    76 neopterin
    77 nesiritide infusion
    78 nonsurvivors
    79 novel biomarkers
    80 paradigm
    81 part
    82 patients
    83 peptides
    84 plasma
    85 plasma levels
    86 plasma of patients
    87 posthospital nonsurvivors
    88 postinfusion
    89 potential
    90 procalcitonin
    91 prognostic value
    92 progression
    93 proportional hazards model
    94 prospective study
    95 reduction
    96 response
    97 results
    98 risk
    99 risk stratification
    100 significant acute reduction
    101 stratification
    102 study
    103 terminals
    104 therapy
    105 therapy-monitoring potential
    106 type natriuretic peptide
    107 use
    108 values
    109 schema:name Response of Novel Biomarkers to BNP Infusion in Patients with Decompensated Heart Failure: A Multimarker Paradigm
    110 schema:pagination 526-535
    111 schema:productId N1018ad22c91c4547a327619866b8bf65
    112 N211403481da74aa79964cd75ec40de45
    113 N60daba938db7429982e2fbbe8d41b369
    114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003860827
    115 https://doi.org/10.1007/s12265-009-9121-x
    116 schema:sdDatePublished 2022-01-01T18:20
    117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    118 schema:sdPublisher N985e5c226a794efb94358d7d40ba0a7b
    119 schema:url https://doi.org/10.1007/s12265-009-9121-x
    120 sgo:license sg:explorer/license/
    121 sgo:sdDataset articles
    122 rdf:type schema:ScholarlyArticle
    123 N0185d57a4691468aaf35e470e46ffd6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    124 schema:name Minnesota
    125 rdf:type schema:DefinedTerm
    126 N06081110322d453f8f51aa50a373d4ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    127 schema:name Treatment Outcome
    128 rdf:type schema:DefinedTerm
    129 N1018ad22c91c4547a327619866b8bf65 schema:name pubmed_id
    130 schema:value 20560012
    131 rdf:type schema:PropertyValue
    132 N122aa5174ba5473fa5bc1b23ad9f8e24 schema:issueNumber 4
    133 rdf:type schema:PublicationIssue
    134 N18ed9a7bc5b840cbb8efbbad86ebbd8e rdf:first sg:person.0646201724.19
    135 rdf:rest Ne9c3d4160ab641959eab3651d85ae239
    136 N211403481da74aa79964cd75ec40de45 schema:name dimensions_id
    137 schema:value pub.1003860827
    138 rdf:type schema:PropertyValue
    139 N279a3f4175344df0a522d4c2ce1915f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Kaplan-Meier Estimate
    141 rdf:type schema:DefinedTerm
    142 N47c51ca68bd044d7ba57192db9f0155c rdf:first sg:person.01234574026.84
    143 rdf:rest N82dea78efd03479cbaca1bc4f94b123b
    144 N550e9a6fda3e42d0b80d6f3df22038e6 rdf:first sg:person.01166460626.19
    145 rdf:rest N47c51ca68bd044d7ba57192db9f0155c
    146 N60daba938db7429982e2fbbe8d41b369 schema:name doi
    147 schema:value 10.1007/s12265-009-9121-x
    148 rdf:type schema:PropertyValue
    149 N6e1a83598ecf4afd8d1cf7882565b511 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Infusions, Intravenous
    151 rdf:type schema:DefinedTerm
    152 N7546af984e594cff86c8e5d90302255b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Natriuretic Peptide, Brain
    154 rdf:type schema:DefinedTerm
    155 N765c0cc58c684aa2a110011caae52d95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Protein Precursors
    157 rdf:type schema:DefinedTerm
    158 N82dea78efd03479cbaca1bc4f94b123b rdf:first sg:person.01321577767.50
    159 rdf:rest N18ed9a7bc5b840cbb8efbbad86ebbd8e
    160 N839860373c2644ff84270bcb8e130900 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Calcitonin Gene-Related Peptide
    162 rdf:type schema:DefinedTerm
    163 N854fcaeff14c42119efd64ec91d63d12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Female
    165 rdf:type schema:DefinedTerm
    166 N87a2a70101cc40b68f272797b2e80ccc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name Neopterin
    168 rdf:type schema:DefinedTerm
    169 N8e165edd95bb4e87b1627424a3c4ab8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Risk Assessment
    171 rdf:type schema:DefinedTerm
    172 N8fe3a4eaf5cf40ae98acaa9dc2b449e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Humans
    174 rdf:type schema:DefinedTerm
    175 N93a679068b334e559db01553ee84b8aa rdf:first sg:person.01142743175.05
    176 rdf:rest rdf:nil
    177 N94e96bebf9d4484bbe79020035db184d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name Risk Factors
    179 rdf:type schema:DefinedTerm
    180 N9505e16e91884b35a9ab6246af332ac1 schema:volumeNumber 2
    181 rdf:type schema:PublicationVolume
    182 N985e5c226a794efb94358d7d40ba0a7b schema:name Springer Nature - SN SciGraph project
    183 rdf:type schema:Organization
    184 Na38a85cd84e0400598deec4a27cdabe6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name Calcitonin
    186 rdf:type schema:DefinedTerm
    187 Nadcc9e33cad6444fa22fa16d2029f96c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    188 schema:name Male
    189 rdf:type schema:DefinedTerm
    190 Nadf10883e15a4688839e9e7d05e77e1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    191 schema:name Aged
    192 rdf:type schema:DefinedTerm
    193 Nb1caf08914ed489cb20bef8d75ee2965 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    194 schema:name Glycopeptides
    195 rdf:type schema:DefinedTerm
    196 Nb570b30175684c9e8f75abb0b6acc7d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    197 schema:name Cardiovascular Agents
    198 rdf:type schema:DefinedTerm
    199 Nb5b39bb2166a457ab4d0a0d6f873fd03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    200 schema:name Predictive Value of Tests
    201 rdf:type schema:DefinedTerm
    202 Nb6c475ba2c5e4831b7f3436b68acac9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    203 schema:name Time Factors
    204 rdf:type schema:DefinedTerm
    205 Nbf0c9b3e4e174f3cb88f84ba635b3a10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    206 schema:name Atrial Natriuretic Factor
    207 rdf:type schema:DefinedTerm
    208 Nc0a6a925578248a4a65570bcaa3e0ac4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    209 schema:name Biomarkers
    210 rdf:type schema:DefinedTerm
    211 Nd7bd502650af47779a63c392751c7487 rdf:first sg:person.0707647370.62
    212 rdf:rest Nf4e6c80ffa13439b950f261cc001df24
    213 Ndfc41442814345c1a78b4b20d6a1ee6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    214 schema:name Drug Monitoring
    215 rdf:type schema:DefinedTerm
    216 Ne9c3d4160ab641959eab3651d85ae239 rdf:first sg:person.01136323224.23
    217 rdf:rest Nd7bd502650af47779a63c392751c7487
    218 Nf4e6c80ffa13439b950f261cc001df24 rdf:first sg:person.01014762623.23
    219 rdf:rest N93a679068b334e559db01553ee84b8aa
    220 Nffa8a84d0e954918b5ca21cf328814a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    221 schema:name Heart Failure
    222 rdf:type schema:DefinedTerm
    223 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    224 schema:name Medical and Health Sciences
    225 rdf:type schema:DefinedTerm
    226 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    227 schema:name Cardiorespiratory Medicine and Haematology
    228 rdf:type schema:DefinedTerm
    229 sg:journal.1039754 schema:issn 1937-5387
    230 1937-5395
    231 schema:name Journal of Cardiovascular Translational Research
    232 schema:publisher Springer Nature
    233 rdf:type schema:Periodical
    234 sg:person.01014762623.23 schema:affiliation grid-institutes:None
    235 schema:familyName Bergmann
    236 schema:givenName Andreas
    237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014762623.23
    238 rdf:type schema:Person
    239 sg:person.01136323224.23 schema:affiliation grid-institutes:None
    240 schema:familyName Struck
    241 schema:givenName Joachim
    242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136323224.23
    243 rdf:type schema:Person
    244 sg:person.01142743175.05 schema:affiliation grid-institutes:grid.66875.3a
    245 schema:familyName Jaffe
    246 schema:givenName Allan S.
    247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142743175.05
    248 rdf:type schema:Person
    249 sg:person.01166460626.19 schema:affiliation grid-institutes:grid.66875.3a
    250 schema:familyName Miller
    251 schema:givenName Wayne L.
    252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166460626.19
    253 rdf:type schema:Person
    254 sg:person.01234574026.84 schema:affiliation grid-institutes:grid.66875.3a
    255 schema:familyName Hartman
    256 schema:givenName Karen A.
    257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234574026.84
    258 rdf:type schema:Person
    259 sg:person.01321577767.50 schema:affiliation grid-institutes:grid.66875.3a
    260 schema:familyName Hodge
    261 schema:givenName David O.
    262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01321577767.50
    263 rdf:type schema:Person
    264 sg:person.0646201724.19 schema:affiliation grid-institutes:grid.66875.3a
    265 schema:familyName Hartman
    266 schema:givenName Stacy
    267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646201724.19
    268 rdf:type schema:Person
    269 sg:person.0707647370.62 schema:affiliation grid-institutes:None
    270 schema:familyName Morgenthaler
    271 schema:givenName Nils G.
    272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707647370.62
    273 rdf:type schema:Person
    274 sg:pub.10.1023/a:1022564803093 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032855376
    275 https://doi.org/10.1023/a:1022564803093
    276 rdf:type schema:CreativeWork
    277 grid-institutes:None schema:alternateName B.R.A.H.M.S. Aktiengesellschaft, Hennigsdorf, Berlin, Germany
    278 schema:name B.R.A.H.M.S. Aktiengesellschaft, Hennigsdorf, Berlin, Germany
    279 rdf:type schema:Organization
    280 grid-institutes:grid.66875.3a schema:alternateName Mayo Clinic, 200 First Street, SW, 55905, Rochester, MN, USA
    281 schema:name Mayo Clinic, 200 First Street, SW, 55905, Rochester, MN, USA
    282 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...